Total amount raised
$1.6 Billions
Latest funding date
4/1/2024
Location
Ginkgo Bioworks has successfully raised significant funding over multiple rounds, attracting a diverse group of investors. The company specializes in biotechnology and synthetic biology, offering innovative solutions across various industries.
Keep reading to explore the intricacies of Ginkgo Bioworks' fundraising journey and the investors backing this pioneering platform.
What Is Ginkgo Bioworks?
Ginkgo Bioworks, founded in 2008, is a biotechnology company based in Boston, Massachusetts. The company specializes in developing biological engineering products and custom microbes across various markets.
Founded by Austin Che, Barry Canton, Jason Kelly, Reshma Shetty, and Tom Knight, Ginkgo Bioworks leverages synthetic biology to design, engineer, develop, test, and license organisms. Their work spans multiple industries, including agriculture, biopharma, and industrial biotech.
With a workforce of 1001-5000 employees, Ginkgo Bioworks continues to innovate and expand its capabilities, offering R&D tools and solutions to meet diverse market needs.
How Much Funding Has Ginkgo Bioworks Raised?
- Series C
- Amount Raised: $100M
- Date: June 2016
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand their synthetic biology platform and increase R&D capabilities.
- Series D
- Amount Raised: $275M
- Date: December 2017
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and enhance their organism engineering capabilities.
- Series E
- Amount Raised: $290M
- Date: September 2019
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate growth and support new partnerships in various industries.
- Series F
- Amount Raised: $70M
- Date: May 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop their bioengineering platform and expand market reach.
- Series B
- Amount Raised: Not publicly disclosed
- Date: June 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance their technological infrastructure and support ongoing projects.
- Post-IPO Equity
- Amount Raised: $775M
- Date: September 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund strategic acquisitions and expand their product offerings.
- Grant
- Amount Raised: Not publicly disclosed
- Date: September 2023
- Lead Investors: Agriculture and Food Research Initiative
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support agricultural biotechnology research and development.
- Grant
- Amount Raised: Not publicly disclosed
- Date: October 2023
- Lead Investors: Centers for Disease Control and Prevention
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance public health initiatives and disease prevention technologies.
- Grant
- Amount Raised: Not publicly disclosed
- Date: December 2023
- Lead Investors: Bill & Melinda Gates Foundation
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop antibody therapeutics for HIV and malaria.
- Grant
- Amount Raised: Not publicly disclosed
- Date: April 2024
- Lead Investors: Bill & Melinda Gates Foundation
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue the development of antibody therapeutics for global health challenges.
Total Amount Raised: $1.51B. Current Valuation: Not publicly disclosed.
Key Investors
- Bill & Melinda Gates Foundation
- Details: The Bill & Melinda Gates Foundation is a philanthropic organization founded by Bill and Melinda Gates. It focuses on improving global health, reducing extreme poverty, and expanding educational opportunities.
- Investment Focus Areas: Global health, education, poverty alleviation.
- Notable Investments: Gavi, the Vaccine Alliance, Global Fund to Fight AIDS, Tuberculosis and Malaria, PATH.
- Centers for Disease Control and Prevention (CDC)
- Details: The CDC is a national public health institute in the United States. It focuses on protecting public health and safety through the control and prevention of disease, injury, and disability.
- Investment Focus Areas: Public health, disease prevention, health promotion.
- Notable Investments: Not publicly disclosed.
- Agriculture and Food Research Initiative (AFRI)
- Details: AFRI is a competitive grant program within the USDA's National Institute of Food and Agriculture. It supports research, education, and extension projects in food and agricultural sciences.
- Investment Focus Areas: Agriculture, food security, environmental sustainability.
- Notable Investments: Not publicly disclosed.
- Series E Investors
- Details: The Series E funding round raised $290M with participation from multiple investors. Specific names of the investors were not publicly disclosed.
- Investment Focus Areas: Biotechnology, synthetic biology, industrial biotech.
- Notable Investments: Not publicly disclosed.
- Series D Investors
- Details: The Series D funding round raised $275M with participation from multiple investors. Specific names of the investors were not publicly disclosed.
- Investment Focus Areas: Biotechnology, synthetic biology, industrial biotech.
- Notable Investments: Not publicly disclosed.
What's Next for Ginkgo Bioworks?
Ginkgo Bioworks is poised to revolutionize healthcare in low- and middle-income countries with its innovative cell-based technology for HIV and malaria antibody therapeutics. This opportunity, backed by the Bill & Melinda Gates Foundation, aims to create a sustainable and cost-effective delivery method for protein therapeutics, potentially impacting millions of lives.
As the company advances this groundbreaking project, future fundraising opportunities are likely to emerge from global health organizations and potential partnerships with pharmaceutical companies. However, Ginkgo Bioworks will need to navigate technical and regulatory challenges to ensure the technology's scalability and accessibility.
Use Clay to Get Funding Data
Sales professionals, take advantage of Clay's platform to access comprehensive fundraising data on companies like Ginkgo Bioworks and gather other critical business insights. Sign up for free today and unlock the potential to drive your sales strategy with unparalleled data and insights.
